Mutation of BRAF is uncommon in AML FAB type M1 and M2
Leukemia (2003) 17, 274-275. doi:10.1038/sj.leu.2402787 TO THE EDITOR BRAF (v-raf murine sarcoma viral oncogene homolog B1) is one of three related serine/threonine RAF kinases that form an essential part of the RAS-MAP kinase signalling pathway. 1 It has been shown that activating RAS mutations occur in up to 30% of AML cases at presentation 2 and that MAP kinase is activated in approximately 50% of AML samples, 3 suggesting that this pathway may be important in leukaemogenesis. Recent work by Davies et al 4 has identified BRAF mutations in a variety of cancer cell lines and primary human cancers. These all affect the kinase domain and have been shown to have transforming activity irrespective of RAS mutation status. While the majority of such BRAF mutations was identified in melanoma, colorectal cancer and ovarian tumours, no primary AML samples and only eight AML cell lines were screened. We therefore set out to determine the incidence of BRAF mutations in our AML patient population.
DNA was extracted by standard phenol-chloroform method from the peripheral blood or bone marrow of 104 patients with AML-M1 (56) and M2 (48). These patients were referred to St Bartholomew's Hospital between 1985 and 2001 and were identified from the historical database. Seventy were male and the median age was 53 years (range 18-83). Six cases were of secondary AML. Patients were subdivided according to standard Medical Research Council cytogenetic risk-groups into 'good' (20), 'intermediate' (67) and 'poor' (17). Patients were selected for analysis based on sample availability and assessment of disease infiltration within the sample. Ninety-eight samples were taken at diagnosis and six were taken at relapse. The study was carried out in accordance with the requirements of the local ethical committee. DNA was also extracted from the lung adenocarcinoma cell line NCI-H1395 (ATCC Cat. No. 45508) and the colorectal cancer cell line HT-29 (Central Cell Services Cancer Research UK). These were used as positive controls as they had previously been shown to have BRAF mutations of exon 11 G1403C/G468A (NCI-H1395) and exon 15 T1796A/ V599E (HT29), respectively. 4 Mutation analysis was restricted to exon 11 and 15 of BRAF as all previously reported mutations cluster to these two exons. Mutation screening was carried out using a PCR-single stranded conformational polymorphism (SSCP) analysis (GenePhor II, Amersham-Pharmacia Biotech, Bucks, UK). Exon 11 (313bp) and exon 15 (224bp) were individually amplified from 50 ng of patient or cell line DNA using an annealing temperature of 52°C. The primers and conditions used have been described previously. 4 PCR products were denatured in formamide and electrophoresed at 15°C using the CleanGene system and Disc Buffer Kit pH 8.3. Banding patterns were visualised by silver staining using the Plus One Silver Staining kit (Amersham-Pharmacia Biotech) and a Hoefer automated gel stainer. Aberrant SSCP band shifts were detected for the two positive controls (HT-29 and NCI-H1395) and in exon 11 of patient 52. Following removal of nucleotides and primers using Microcon PCR columns (Millipore, Bedford, MA, USA), aberrantly migrating PCR fragments were sequenced directly using an ABI 377 DNA sequencer (Perkin Elmer, Foster City, CA, USA). Sequence analysis for patient 52 identified a novel synonymous G1329A/R443R polymorphism. Representative SSCP results are shown in Figure 1 . The RAS/MAP kinase pathway is deregulated in a significant proportion of cases of AML. Although activating RAS mutations are important, constitutive activation of the MAP kinase pathway can occur independently of RAS mutation. 5 Explanations for this may include alteration in alternative targets for activated RAS such as phosphatidylinositol-3-OH-kinase or in other downstream components of the kinase cascade such as BRAF. Although BRAF mutations appear to be associated with cancers having RAS mutations, the absence of BRAF mutations in 104 AML patient samples analysed in this study suggests that BRAF is not a common target of mutation in AML.
ML Smith
Cancer 
